| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/SJ.KI.5002731 |
| P8608 | Fatcat ID | release_6tqt3qkvfzad7dj3fnlxld5fyq |
| P698 | PubMed publication ID | 18094678 |
| P5875 | ResearchGate publication ID | 5753744 |
| P2093 | author name string | Nelson PJ | |
| Meijer L | |||
| Zuk A | |||
| Ibraghimov-Beskrovnaya O | |||
| Obligado SH | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 684-690 | |
| P577 | publication date | 2007-12-19 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases | |
| P478 | volume | 73 |
| Q39961844 | A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286. |
| Q37336692 | ATP-noncompetitive inhibitors of CDK-cyclin complexes. |
| Q35056271 | Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy |
| Q38299707 | Cell cycle control in the kidney |
| Q84639413 | Conditional ablation of glycogen synthase kinase 3β in postnatal mouse kidney |
| Q37602210 | Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents |
| Q38100203 | Cyclin-dependent kinase inhibitors closer to market launch? |
| Q37697797 | Cyclin-dependent kinase inhibitors: a survey of recent patent literature |
| Q42135408 | Deconstructing GSK-3: The Fine Regulation of Its Activity |
| Q35303442 | Enhanced glycogen synthase kinase-3β activity mediates podocyte apoptosis under diabetic conditions. |
| Q35866243 | Expression of GSK-3β in renal allograft tissue and its significance in pathogenesis of chronic allograft dysfunction |
| Q33711281 | GSK3beta promotes apoptosis after renal ischemic injury. |
| Q35121215 | Glycogen synthase kinase 3β orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion |
| Q41679884 | Glycogen synthase kinase-3β inhibitor ameliorates imbalance of connexin 43 in an acute kidney injury model |
| Q37332647 | Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis |
| Q38636263 | Lithium in the Kidney: Friend and Foe? |
| Q28564562 | Overlapping genes in Nalp6/PYPAF5 locus encode two V2-type vasopressin isoreceptors: angiotensin-vasopressin receptor (AVR) and non-AVR |
| Q37290939 | Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection |
| Q36701966 | Regulatory role of GSK-3 β on NF- κ B, nitric oxide, and TNF- α in group A streptococcal infection |
| Q51195315 | Silencing of p53 RNA through transarterial delivery ameliorates renal tubular injury and downregulates GSK-3β expression after ischemia-reperfusion injury. |
| Q37280604 | Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period |
| Q37436067 | The cell cycle and acute kidney injury |
| Q53082626 | Two non-invasive GFR-estimation methods in rat models of polycystic kidney disease: 3.0 Tesla dynamic contrast-enhanced MRI and optical imaging. |
| Q38356739 | Understanding podocytopathy and its relevance to clinical nephrology |
Search more.